SG11201706657PA - Compounds for improving the half-life of von willebrand factor - Google Patents
Compounds for improving the half-life of von willebrand factorInfo
- Publication number
- SG11201706657PA SG11201706657PA SG11201706657PA SG11201706657PA SG11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA SG 11201706657P A SG11201706657P A SG 11201706657PA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- improving
- life
- von willebrand
- willebrand factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15158088 | 2015-03-06 | ||
| PCT/EP2016/054650 WO2016142289A1 (en) | 2015-03-06 | 2016-03-04 | Compounds for improving the half-life of von willebrand factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706657PA true SG11201706657PA (en) | 2017-09-28 |
Family
ID=52629453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706657PA SG11201706657PA (en) | 2015-03-06 | 2016-03-04 | Compounds for improving the half-life of von willebrand factor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180043012A1 (https=) |
| EP (1) | EP3265489B1 (https=) |
| JP (1) | JP6704420B2 (https=) |
| KR (1) | KR20170125942A (https=) |
| CN (1) | CN107428831A (https=) |
| AU (1) | AU2016231328B2 (https=) |
| BR (1) | BR112017017852A2 (https=) |
| CA (1) | CA2978134A1 (https=) |
| DK (1) | DK3265489T3 (https=) |
| ES (1) | ES2755449T3 (https=) |
| SG (1) | SG11201706657PA (https=) |
| WO (1) | WO2016142289A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301332A (en) * | 2020-09-23 | 2023-05-01 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of autoantibody-mediated conditions |
| US20240002861A1 (en) * | 2020-11-24 | 2024-01-04 | Band Therapeutics, Llc | Compositions and methods for treatment of bleeding disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| PT1754718E (pt) * | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| CA2465004A1 (en) * | 2003-05-19 | 2004-11-19 | National Institute For Biological Standards And Control | Composition |
| JP2005132796A (ja) * | 2003-10-31 | 2005-05-26 | Tatsuro Irimura | 肉芽組織形成性疾患の治療のための医薬組成物および方法 |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| EP2662083A1 (en) * | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
| EP2669679A1 (en) * | 2012-05-28 | 2013-12-04 | Universitätsklinikum Hamburg-Eppendorf | Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain |
| HRP20200007T1 (hr) * | 2012-07-11 | 2020-03-20 | Bioverativ Therapeutics Inc. | Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba |
| SG10201710616XA (en) * | 2013-06-28 | 2018-02-27 | Biogen Ma Inc | Thrombin cleavable linker with xten and its uses thereof |
-
2016
- 2016-03-04 JP JP2017564947A patent/JP6704420B2/ja not_active Expired - Fee Related
- 2016-03-04 WO PCT/EP2016/054650 patent/WO2016142289A1/en not_active Ceased
- 2016-03-04 SG SG11201706657PA patent/SG11201706657PA/en unknown
- 2016-03-04 EP EP16708978.8A patent/EP3265489B1/en active Active
- 2016-03-04 CA CA2978134A patent/CA2978134A1/en not_active Abandoned
- 2016-03-04 BR BR112017017852-4A patent/BR112017017852A2/pt not_active Application Discontinuation
- 2016-03-04 AU AU2016231328A patent/AU2016231328B2/en not_active Ceased
- 2016-03-04 CN CN201680014068.2A patent/CN107428831A/zh active Pending
- 2016-03-04 DK DK16708978.8T patent/DK3265489T3/da active
- 2016-03-04 US US15/555,828 patent/US20180043012A1/en not_active Abandoned
- 2016-03-04 KR KR1020177028209A patent/KR20170125942A/ko not_active Withdrawn
- 2016-03-04 ES ES16708978T patent/ES2755449T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016231328A1 (en) | 2017-10-26 |
| JP2018510213A (ja) | 2018-04-12 |
| JP6704420B2 (ja) | 2020-06-03 |
| WO2016142289A1 (en) | 2016-09-15 |
| EP3265489B1 (en) | 2019-05-08 |
| CN107428831A (zh) | 2017-12-01 |
| CA2978134A1 (en) | 2016-09-15 |
| AU2016231328B2 (en) | 2018-07-05 |
| BR112017017852A2 (pt) | 2018-04-10 |
| DK3265489T3 (da) | 2019-07-15 |
| US20180043012A1 (en) | 2018-02-15 |
| ES2755449T3 (es) | 2020-04-22 |
| KR20170125942A (ko) | 2017-11-15 |
| EP3265489A1 (en) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804739B (en) | Novel compounds | |
| IL255067A0 (en) | new compounds | |
| GB201610147D0 (en) | Novel compounds | |
| GB201604647D0 (en) | Novel compounds | |
| GB201604638D0 (en) | Novel compounds | |
| GB201602854D0 (en) | Novel compounds | |
| GB201603779D0 (en) | Novel compounds | |
| GB201516243D0 (en) | Novel compounds | |
| GB201522768D0 (en) | Novel compounds | |
| GB201521109D0 (en) | Novel compounds | |
| GB201506871D0 (en) | Novel compounds | |
| GB201501462D0 (en) | Novel compounds | |
| GB201522179D0 (en) | Novel compounds | |
| GB201504565D0 (en) | Novel compounds | |
| GB201613163D0 (en) | Novel compounds | |
| SG11201706659WA (en) | Modified von willebrand factor having improved half-life | |
| EP3164150A4 (en) | Modified von willebrand factor | |
| IL255711A (en) | Methods for preparing modified von Willebrand factor | |
| GB201502675D0 (en) | Novel compounds | |
| SG11201706657PA (en) | Compounds for improving the half-life of von willebrand factor | |
| GB201601301D0 (en) | Novel compounds | |
| AU2014902532A0 (en) | Modified von willebrand factor | |
| GB201610956D0 (en) | Novel compounds | |
| GB201610392D0 (en) | Novel compounds | |
| GB201610391D0 (en) | Novel compounds |